Fusion Antibodies PLC
LSE:FAB
Fusion Antibodies PLC
LSE:FAB
Price:
14
GBX
Market Closed
Market Cap:
£17.5m
Balance Sheet
Balance Sheet Decomposition
Fusion Antibodies PLC
Fusion Antibodies PLC
Balance Sheet Decomposition is not available for
Fusion Antibodies PLC
Fusion Antibodies PLC
Balance Sheet
Fusion Antibodies PLC
Fusion Antibodies PLC
Currency: GBP
| Mar-2015 | Mar-2016 | Mar-2017 | Mar-2018 | Mar-2019 | Mar-2020 | Mar-2021 | Mar-2022 | Mar-2023 | Mar-2024 | Mar-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & Cash Equivalents |
0
|
0
|
0
|
4
|
2
|
2
|
3
|
2
|
0
|
1
|
0
|
|
| Cash Equivalents |
0
|
0
|
0
|
4
|
2
|
2
|
3
|
2
|
0
|
1
|
0
|
|
| Total Receivables |
0
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
0
|
0
|
|
| Accounts Receivables |
0
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
0
|
0
|
0
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Inventory |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
0
|
0
|
|
| Other Current Assets |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
0
|
0
|
0
|
|
| Total Current Assets |
0
|
1
|
1
|
6
|
3
|
3
|
5
|
4
|
2
|
2
|
1
|
|
| PP&E Net |
0
|
0
|
0
|
1
|
2
|
1
|
1
|
1
|
0
|
0
|
0
|
|
| PP&E Gross |
0
|
0
|
0
|
1
|
0
|
1
|
1
|
1
|
0
|
0
|
0
|
|
| Accumulated Depreciation |
1
|
1
|
1
|
1
|
0
|
2
|
2
|
3
|
3
|
3
|
3
|
|
| Intangible Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
1
|
1
|
1
|
1
|
2
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
0
N/A
|
2
+404%
|
2
+15%
|
7
+234%
|
6
-13%
|
6
-3%
|
6
-3%
|
5
-16%
|
2
-58%
|
2
+17%
|
1
-45%
|
|
| Liabilities | ||||||||||||
| Accounts Payable |
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Accrued Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Current Liabilities |
0
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
0
N/A
|
0
+104%
|
0
+9%
|
1
+41%
|
1
+40%
|
1
+38%
|
1
-12%
|
1
+14%
|
1
-24%
|
1
-33%
|
1
+4%
|
|
| Equity | ||||||||||||
| Common Stock |
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
4
|
4
|
|
| Retained Earnings |
7
|
5
|
5
|
1
|
0
|
1
|
4
|
5
|
8
|
10
|
11
|
|
| Additional Paid In Capital |
6
|
6
|
6
|
5
|
5
|
5
|
8
|
8
|
8
|
8
|
8
|
|
| Total Equity |
0
N/A
|
1
+761%
|
2
+17%
|
7
+285%
|
5
-19%
|
5
-10%
|
5
-1%
|
4
-22%
|
1
-70%
|
2
+60%
|
1
-63%
|
|
| Total Liabilities & Equity |
0
N/A
|
2
+404%
|
2
+15%
|
7
+234%
|
6
-13%
|
6
-3%
|
6
-3%
|
5
-16%
|
2
-58%
|
2
+17%
|
1
-45%
|
|
| Shares Outstanding | ||||||||||||
| Common Shares Outstanding |
22
|
22
|
22
|
22
|
22
|
22
|
26
|
26
|
26
|
95
|
105
|
|
Switch to:
Switch to:
See Also
Discover More
